Results 21 to 30 of about 33,250 (191)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis

open access: yesFrontiers in Oncology, 2020
Numerous studies have documented ultrastructural abnormalities in malignant megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of these cells in spleen, an important extramedullary site in this disease, was not investigated
Maria Zingariello   +8 more
doaj   +1 more source

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

open access: yesHaematologica
Not available.
Giacomo Coltro   +17 more
doaj   +1 more source

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2015
Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare ...
Ristić Slobodan   +5 more
doaj   +1 more source

JAK2 rs10974944 is associated with both V617F‐positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker

open access: yesMolecular Genetics & Genomic Medicine, 2022
The JAK2 gene encodes for a non‐receptor tyrosine kinase that plays a key role in the JAK/STAT signaling transfer pathway. Genetic polymorphisms of this gene have been indicated to be associated with myeloproliferative neoplasm‐associated thrombosis in ...
Nguyen Thy Ngoc   +3 more
doaj   +1 more source

Epigenetics in myeloproliferative neoplasms

open access: yesFrontiers in Oncology, 2023
The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis.
Graeme Greenfield, Mary Frances McMullin
doaj   +1 more source

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

open access: yesHaematologica
Not available.
Gaia Ciolli   +16 more
doaj   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

open access: yesHematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro   +11 more
doaj   +1 more source

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

open access: yesAdvances in Hematology, 2012
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms.
Mar Bellido, Peter A. W. te Boekhorst
doaj   +1 more source

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2015
Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative ...
Renata Mendes de Freitas   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy